Alectinib

Definition

An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.

Also known as 5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-, AF 802, AF-802, AF802, Alecensa, ALECTINIB, ALK Inhibitor RO5424802, CH 5424802, CH-5424802, CH5424802, RG 7853, RG-7853, RG7853, RO 5424802, RO-5424802, RO5424802 — per NCIT

Also identified as

• ATC L01ED03 per RXNORM
• NCIT NCIT:C101790 per NCIT
• SCTID 716039000 per RXNORM
• SCTID 781316007 per RXNORM
• UNII LIJ4CT1Z3Y per RXNORM

Indications

Organ Effects

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.